Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112108 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Signalling, 2025. Verfasst von Dayong Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, North China University of Science and Technology, 21 Bohai Road, Caofeidian District, Tangshan, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Molecular Targeted Therapy, Proto-Oncogene Proteins c-yes. Die Arbeit nennt 93 Literaturangaben. Gefördert von: University of Science and Technology of China, Department of Science and Technology of Liaoning Province, Hebei Provincial Natural Science Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
YES1 (Yamaguchi sarcoma virus homolog 1), a non-receptor tyrosine kinase of the SRC family (SFK), has been abnormally amplified or mutated in several types of solid tumors. The alteration of YES1 impacted multiple biological processes, including promoting tumor progression and metastasis, especially, producing cancer therapy resistance via bypass pathways. Thus, YES1 can serve as a druggable target to overcome drug resistance and suppress tumor growth. Due to toxicity and lack of selectivity, several SFK-targeted agents in clinical trials were limited for further investigation. Recently, the emerging role of YES1-selective inhibitors and the promising approach of combinational therapy have exhibited synergistic anti-tumor effects. Herein, we summarize the multiple mechanisms of YES1-driving tumor progression and resistance, focusing on YES1 inhibitors in combination with other therapies. We also discuss the oncogenic mechanism of the YES1-YAP1 pathway, EGFR-YES1 crosstalk, the roles of YES1 in the tumor microenvironment, and the synthetic lethal effect of YES1 inhibitors. Taken together, available evidences strongly suggest that targeting YES1 could be a promising sensitization strategy for cancer treatment and improve the patient's quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, North China University of Science and Technology, 21 Bohai Road, Caofeidian District, Tangshan, China.
- Teaching and Experiment Center, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
- Department of Oncology and Cancer Therapeutics Program, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: edward.chu@einsteinmed.edu.
- Department of Oncology and Cancer Therapeutics Program, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: ning.wei@einsteinmed.edu.
Förderung
- University of Science and Technology of China
- Department of Science and Technology of Liaoning Province
- Hebei Provincial Natural Science Foundation
- National Cancer Institute
Zitieren
APA
Zheng, D., Wang, Y., Li, J., Zhang, G., Chu, E., & Wei, N. (2025). Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112108
Vancouver
Zheng D, Wang Y, Li J, Zhang G, Chu E, Wei N. Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112108
BibTeX
@article{Zheng2025,
author = {Zheng, Dayong and Wang, Yiran and Li, Jun and Zhang, Gang and Chu, Edward and Wei, Ning},
title = {Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112108}
}
EUVIMED